Ventured Growth with Hercules Capital · Hercules Capital
#34 - The Evolution of Biotech Deals: From Pharma Consolidation to Innovation | Stephen Sands
·47 min·1 clip
In his 35 years at Lazard, Stephen Sands has been directly involved in many of the M&A transactions that shaped modern biotech.
As heard by us
A clear look at how biotech dealmaking has shifted toward targeted innovation and earlier-stage alliances.
Stephen Sands uses years in healthcare M&A to track how biotech dealmaking has changed as pharma has consolidated and attention has shifted toward innovation, targeted therapies, and earlier-stage alliances.
Why you'd press play
If you want the deal logic behind biotech's shift from consolidation to targeted innovation, press play.
Listen to the show on